Cargando…

Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential

SIMPLE SUMMARY: In chronic myeloid leukemia (CML), a neoplasm brilliantly taken care of by a molecularly targeted therapeutic approach, the achievement of cure is nevertheless prevented by the maintenance of a small subset of treatment-resistant leukemia stem cells (LSCs), sustaining the so-called m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poteti, Martina, Menegazzi, Giulio, Peppicelli, Silvia, Tusa, Ignazia, Cheloni, Giulia, Silvano, Angela, Mancini, Caterina, Biagioni, Alessio, Tubita, Alessandro, Mazure, Nathalie M., Lulli, Matteo, Rovida, Elisabetta, Dello Sbarba, Persio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430815/ https://www.ncbi.nlm.nih.gov/pubmed/34503182 http://dx.doi.org/10.3390/cancers13174372

Ejemplares similares

Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction
por: Silvano, Angela, et al.
Publicado: (2022)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
por: Cheloni, Giulia, et al.
Publicado: (2017)

Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy
por: Tubita, Alessandro, et al.
Publicado: (2020)

The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells
por: Tusa, Ignazia, et al.
Publicado: (2021)

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
por: Rovida, Elisabetta, et al.
Publicado: (2014)

Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
por: Tusa, Ignazia, et al.
Publicado: (2018)

Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction
por: Bono, Silvia, et al.
Publicado: (2016)

Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
por: Tubita, Alessandro, et al.
Publicado: (2022)

Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy
por: Tubita, Alessandro, et al.
Publicado: (2021)

Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress
por: Tusa, Ignazia, et al.
Publicado: (2023)

Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
por: Bono, Silvia, et al.
Publicado: (2018)

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
por: Barbetti, Valentina, et al.
Publicado: (2013)

Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9
por: Barbetti, Valentina, et al.
Publicado: (2013)

The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2013)

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a “hypoxic” environment
por: Rovida, Elisabetta, et al.
Publicado: (2014)

Targeting MAPK in Cancer 2.0
por: Rovida, Elisabetta, et al.
Publicado: (2022)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
por: Morandi, Andrea, et al.
Publicado: (2011)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

Low-dose methotrexate enhances cycling of highly anaplastic cancer cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity
por: El-Damasy, Ashraf K., et al.
Publicado: (2023)

Cancer stemness and progression: mitochondria on the stage
por: Chiarugi, Paola, et al.
Publicado: (2015)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation
por: Sontakke, Pallavi, et al.
Publicado: (2016)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

The complex metabolic network gearing the G(1)/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents
por: Stivarou, Theodora, et al.
Publicado: (2015)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l50ikv3qrae5rg14boq7qmj36t